P. Malmström

发表

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial

M. Piérart, MJ van den Bent, D. Áfra, 2005, The Lancet.

Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity

M. Ringnér, L. Saal, P. Malmström, 2007, Proceedings of the National Academy of Sciences.

High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer

M. Ringnér, P. Malmström, Å. Borg, 2010, Breast Cancer Research.

Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis–Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer

Mårten Fernö, Srinivas Veerla, Siker Kimbung, 2015, Clinical Cancer Research.

Estrogen Receptor β Expression Is Associated with Tamoxifen Response in ERα-Negative Breast Carcinoma

L. Saal, M. Fernö, C. Peterson, 2007, Clinical Cancer Research.

Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial

P. Malmström, O. Stål, J. Carstensen, 2011, British Journal of Cancer.

Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy.

J. Bergh, P. Malmström, H. Holte, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer

J. Bergh, P. Malmström, S. Margolin, 2011, Acta oncologica.

Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.

Michael Gnant, Jonas Bergh, Richard Greil, 2016, JAMA.

Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients

R. Greil, J. Bergh, P. Malmström, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.

Jorma Isola, Jonas Bergh, Nils Wilking, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer.

J. Bergh, P. Malmström, L. Hakamies‐Blomqvist, 2003, European journal of cancer.

Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401.

J. Bergh, P. Malmström, B. Erikstein, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

”Evolution of ipsilateral breast cancer decoded by proteogenomics”

Paul Theodor Pyl, M. Fernö, P. Malmström, 2022, bioRxiv.

Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial.

J. Bergh, P. Malmström, J. Carstensen, 2005, Journal of the National Cancer Institute.

Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group.

J. Bergh, P. Malmström, L. Hakamies‐Blomqvist, 2000, European journal of cancer.

Timing of quality of life (QoL) assessments as a source of error in oncological trials.

J. Bergh, P. Malmström, L. Hakamies‐Blomqvist, 2001, Journal of advanced nursing.

Postoperative prognosis in craniopharyngioma with respect to cardiovascular mortality, survival, and tumor recurrence.

P. Malmström, L. Hagmar, C. Nordström, 1998, The Journal of clinical endocrinology and metabolism.

Multimodality treatment of 128 patients with locally advanced breast carcinoma in the era of mammography screening using standard polychemotherapy with 5‐fluorouracil, epirubicin, and cyclophosphamide

J. Bergh, P. Malmström, N. Bengtsson, 1998, Cancer.

Quantitative 201Tl SPET imaging in the follow-up of treatment for brain tumour: A sensitive tool for the early identification of response to chemotherapy?

P. Malmström, E. Ryding, B. Geijer, 2000, Nuclear medicine communications.

Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen

P. Malmström, O. Stål, J. Carstensen, 2017, Acta oncologica.

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.

Hanina Hibshoosh, Xiaomei Wang, Matthew Maurer, 2005, Cancer research.

Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.

Johan Staaf, Mårten Fernö, Markus Ringnér, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.

J. Bergh, P. Malmström, C. Blomqvist, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Basoluminal Carcinoma: A New Biologically and Prognostically Distinct Entity Between Basal and Luminal Breast Cancer

J. Bergh, P. Malmström, B. Erikstein, 2006, Clinical Cancer Research.

Tiling array-CGH for the assessment of genomic similarities among synchronous unilateral and bilateral invasive breast cancer tumor pairs

M. Ringnér, M. Fernö, P. Malmström, 2008, BMC clinical pathology.

Proteogenomics decodes the evolution of human ipsilateral breast cancer

Paul Theodor Pyl, M. Fernö, P. Malmström, 2023, Communications Biology.

Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up

P. Malmström, O. Stål, J. Carstensen, 2013, Breast Cancer Research and Treatment.

TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer

P. Malmström, C. Blomqvist, N. Bengtsson, 2006, Acta oncologica.

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.

J Bogaerts, J. Bergh, P. Malmström, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer

M. Fernö, P. Malmström, F. Feng, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Psychological profile related to malignant tumours of different histopathology

P. Malmström, L. Salford, P. Malmström, 1998, Psycho-oncology.

C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer.

J. Bergh, P. Malmström, K. Franssila, 2002, European journal of cancer.

Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial

J. Bergh, P. Malmström, H. Holte, 2000, The Lancet.

Efficacy and safety of tailored and dose‐dense adjuvant chemotherapy and trastuzumab for resected HER2‐positive breast cancer: Results from the phase 3 PANTHER trial

R. Greil, J. Bergh, P. Malmström, 2019, Cancer.

Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study.

P. Malmström, Ó. Bjarnadóttir, B. Götrick, 2020, Oral surgery, oral medicine, oral pathology and oral radiology.

Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up

M. Fernö, P. Malmström, F. Killander, 2022, British Journal of Cancer.

High CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer

M. Fernö, P. Malmström, P. Bendahl, 2021, npj Breast Cancer.

High CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer

M. Fernö, P. Malmström, P. Bendahl, 2021, NPJ breast cancer.

No increased cardiac mortality or morbidity of radiotherapy in breast cancer patients after breast conserving surgery: 20 years follow-up of the randomised x trial.

L. Holmberg, P. Malmström, E. Wieslander, 2020, International journal of radiation oncology, biology, physics.

Physical Performance, Toxicity, and Quality of Life as Assessed by the Physician and the Patient

P. Malmström, L. Hakamies‐Blomqvist, C. Blomqvist, 2002, Acta oncologica.

Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial.

R. Greil, J. Bergh, P. Malmström, 2019, Journal of Clinical Oncology.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy

P. Malmström, L. Rydén, O. Stål, 2023, Breast.

Estrogen Receptor β Expression Is Associated with Tamoxifen Response in ERα-Negative Breast Carcinoma

L. Saal, M. Fernö, C. Peterson, 2007, Clinical Cancer Research.

S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer.

N. Brünner, M. Fernö, P. Malmström, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast conservation surgery, with and without radiotherapy, in women with lymph node-negative breast cancer: a randomised clinical trial in a population with access to public mammography screening.

L. Holmberg, P. Malmström, C. Ingvar, 2003, European journal of cancer.

No breast cancer subgroup can be spared postoperative radiotherapy after breast-conserving surgery. Fifteen-year results from the Swedish Breast Cancer Group randomised trial, SweBCG 91 RT.

L. Holmberg, P. Malmström, F. Killander, 2016, European journal of cancer.

Psychological profile related to malignant tumours of different histopathology

P. Malmström, L. Salford, Gudmund J. W. Smith, 1998, Psycho-Oncology.

Attitude towards Aggression and Creative Functioning in Patients with Breast Cancer

P. Malmström, L. Salford, Gudmund J. W. Smith, 1998, Perceptual and motor skills.

Reoperation for malignant astrocytomas: personal experience and a review of the literature.

P. Malmström, L. Salford, P. Malmström, 1993, British journal of neurosurgery.

ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer.

M. Fernö, P. Malmström, Å. Borg, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.

L. Saal, M. Fernö, P. Malmström, 2007, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effect of Radiotherapy After Breast-Conserving Surgery Depending on the Presence of Tumor-Infiltrating Lymphocytes: A Long-Term Follow-Up of the SweBCG91RT Randomized Trial.

M. Fernö, P. Malmström, L. Hartman, 2019, Journal of Clinical Oncology.

Tumour microvessel density as predictor of chemotherapy response in breast cancer patients

P. Malmström, C. Blomqvist, B. Østenstad, 2002, British Journal of Cancer.

Effect of Radiotherapy After Breast-Conserving Surgery Depending on the Presence of Tumor-Infiltrating Lymphocytes: A Long-Term Follow-Up of the SweBCG91RT Randomized Trial.

M. Fernö, P. Malmström, P. Malmström, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.

R. Greil, J. Bergh, P. Malmström, 2016, JAMA.